Semaglutide.

⌑ I · The MechanismHow it actually works.

Glucagon-like peptide 1 (GLP-1) is an incretin hormone secreted by L-cells of the distal small intestine in response to meal ingestion. Endogenous GLP-1 has a half-life of approximately 2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide is a synthetic GLP-1 analog modified to resist DPP-4 degradation, extending its half-life to approximately one week — enabling once-weekly subcutaneous dosing.[1]

Semaglutide binds the GLP-1 receptor, which is expressed in multiple tissues. The dominant clinical effects arise from:

• Pancreatic effects — glucose-dependent insulin secretion (only when blood glucose is elevated) and suppression of glucagon. This produces blood glucose lowering without significant hypoglycemia risk in non-insulin-using patients.[1]
• Gastric effects — slowed gastric emptying. Food remains in the stomach longer, prolonging satiety and reducing the post-meal glucose spike.[1]
• Central nervous system effects — GLP-1 receptors in the hypothalamus and brainstem signal satiety and reduce appetite ("food noise" reduction is the colloquial description). This is the dominant mechanism for weight loss.[2]
• Cardiovascular effects — emerging evidence suggests direct GLP-1R effects on vasculature, inflammation, and atherosclerotic plaque progression, distinct from weight loss.[3]

⌑ II · The EvidenceWhat the research actually shows.

• STEP-1 (obesity, n=1,961). Wilding et al. (2021, NEJM) randomized adults without diabetes to semaglutide 2.4 mg/week or placebo for 68 weeks. Semaglutide produced 14.9% mean weight loss vs 2.4% with placebo. The largest weight loss ever recorded in a pharmaceutical RCT for obesity at that point.[4]
• SUSTAIN-6 (T2D cardiovascular outcomes, n=3,297). Marso et al. (2016, NEJM) demonstrated semaglutide reduced major adverse cardiovascular events by 26% in T2D patients with established CVD risk — establishing the cardiovascular safety AND benefit profile.[5]
• SELECT (CV outcomes in non-diabetic obesity, n=17,604). Lincoff et al. (2023, NEJM) demonstrated 20% reduction in major adverse cardiovascular events in patients with obesity but WITHOUT diabetes — establishing semaglutide as cardioprotective beyond its glycemic and weight effects.[6]
• FLOW (kidney outcomes, n=3,533). Semaglutide reduced major kidney disease events by 24% in T2D patients with CKD (2024 results) — extending the benefit profile to renal outcomes.[7]
• Lean mass loss (the tradeoff). Weight lost on semaglutide includes significant lean mass alongside fat. STEP-1 estimated 30-40% of weight lost was lean tissue. Concurrent resistance training and adequate protein (1.0+ g/lb) substantially mitigate this. See protein intake protocol →
• Weight regain after discontinuation. STEP-4 (Rubino et al., 2021, JAMA) showed that discontinuation of semaglutide resulted in regain of two-thirds of lost weight within one year. The medication addresses the biological setpoint while present; the setpoint reasserts when removed.[8]

⌑ III · The ProtocolHow it is actually prescribed.

⌑ IV · Side EffectsWhat to actually watch for.

• Gastrointestinal (most common). Nausea (most common), constipation, diarrhea, vomiting, abdominal pain. Generally improve over weeks. Aggressive titration is the dominant trigger.[1]
• Acute pancreatitis (rare). Discontinue immediately if upper abdominal pain radiating to back develops. Risk modestly elevated but absolute rate low.[1]
• Gallstones / cholecystitis. Rapid weight loss from any cause increases gallstone formation risk. Modestly elevated incidence on GLP-1 therapy.[1]
• Medullary thyroid carcinoma (boxed warning). Animal data showed C-cell tumors in rodents. Human risk has not been demonstrated but the FDA boxed warning remains. Contraindicated in personal or family history of MTC or MEN-2.[1]
• Lean mass loss. The most important non-obvious concern. Protein and resistance training are the countermeasures.
• Hypoglycemia. Rare with semaglutide alone but significant if combined with insulin or sulfonylureas. Dose adjustment of concurrent agents required.[1]
• Suicidal ideation signal (debated). Early post-marketing reports flagged possible psychiatric adverse events; subsequent large registry analyses (FDA, EMA) have NOT confirmed a causal association. Continued surveillance.[1]

⌑ V · Compounded vs. BrandThe sourcing problem.

During FDA-declared shortages of brand semaglutide (Ozempic, Wegovy), compounded versions became widely available through telehealth platforms and compounding pharmacies. The FDA-declared shortage formally ended in early 2025; the legal pathway for compounded semaglutide has narrowed substantially.[9]

Compounded semaglutide is NOT FDA-approved. Quality, purity, and dose consistency vary by compounder. Some compounds contained semaglutide sodium salt or related forms with unverified bioequivalence. Patients should understand the regulatory and quality difference between FDA-approved brand product and compounded alternatives.

⌑ VI · The Codex VerdictWhat this means.

Semaglutide and the broader GLP-1 class represent a genuine paradigm shift in metabolic medicine. The data on weight loss, cardiovascular protection, and renal outcomes is of the highest quality available in pharmaceutical research. This is one of the rare cases where the popular enthusiasm tracks the scientific evidence.

The class is not a substitute for the underlying lifestyle work — it is most effective when paired with adequate protein, resistance training, and continued attention to nutrition. The medication addresses the biological setpoint that defeats most dieters; the lifestyle work converts the weight loss into a functional, sustainable body composition change.

For patients who meet clinical criteria (BMI ≥ 30, or ≥ 27 with comorbidity, or T2D), this represents the strongest pharmaceutical option in its category. Cost, sustained use, and the lean-mass loss tradeoff are the meaningful counterweights.